Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

Anthropic’s biomedicine strategy targets closed-loop drug discovery

AI summary

A 36Kr review examines Anthropic’s biomedicine push, including Claude Science, the Model Hardware Standard for laboratory equipment, protein-design agents, wet-lab partnerships, and the Mithril and Coefficient Bio acquisitions. The review says Anthropic is using Claude to orchestrate molecular-design models such as BoltzGen and is building a “pipeline-in-a-person,” while wet-lab validation remains a constraint. It characterizes biomedicine as Anthropic’s next concentrated investment focus after coding and says the strategy is more focused than OpenAI’s broader life-science activities, though that comparison is editorial judgment.

In-depth insight

Anthropic’s push connects Claude with molecular design, laboratory hardware and experimental validation, providing a concrete view of how it is extending AI agents into drug research workflows.

01.Key Takeaways

⁠•生物医药是 Anthropic 在 Coding 之后,下一个集中投入的高价值方向。药物研发本身要求最顶级的智能,而药物研发过程中每一次关键进展,都能形成可观的资产价值,使 AI 的收费模式从 API 到结果付费成为可能。

⁠•Anthropic 现阶段的重点在于尽快 close the loop。随着计算能力提高分子设计的小 loop 更快跑通,瓶颈更多转向湿实验。分子设计已经可以快速生成,因此 Anthropic 最快 close the loop 的领域就是用 Claude 去调用 BoltzGen 等分子设计模型,并加速模型在 GPU 上的效率。同时分子的验证仍受制于湿实验,Anthropic 也开始自建实验室并积极与外部实验室合作,以更快获得可靠反馈闭环推进研究。

⁠•我们相信 Anthropic 是 AI for science 方向上最强、也最 serious 的 key player。对比 OpenAI,Anthropic 更聚焦。对比礼来,Anthropic 更 AI Native。OpenAI 虽然在生物领域起步较早,但布局横跨个人健康、医疗服务和生命科学,不如 Anthropic 的聚焦。而礼来作为药企布局 AI 制药的例子,拥有自有数据与管线,主要通过与合作伙伴共建平台的方式布局 AI,目前步伐和组织形态上仍然偏向保守。

#Anthropic#Claude#Claude Science#Model Hardware Standard#BoltzGen#Mithril#Coefficient Bio#Absci#Google DeepMind#AlphaFold#Adaptyv Bio#Twist Bioscience

Original · 28 min readRead the original
Group chat

No comments yet. Start the conversation.